Prevention of Colitis-Associated Cancer Via Oral Administration of M13-Loaded Lipid Nanoparticles

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Sep 28

PMID 37765299

Authors

Dingpei Long

Zahra Alghoul

Junsik Sung

Chunhua Yang

Didier Merlin

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease, is known to increase the risk of colitis-associated cancer (CAC). CAC has been found to be unresponsive to standard chemotherapy regimens, and the current treatments do not utilize effective small-molecule drugs and colon-targeted delivery systems. Previous studies indicated that the M13-nano-liposome (NL) formulation can effectively target the colon and reshape the gut microbiota in ex vivo cultures, generating altered microbial metabolites that can efficiently prevent chronic UC. In this study, we tested the cancer cell uptake ability of the NL formulation and investigated the potential of the M13-NL formulation to prevent CAC in the azoxymethane (AOM)-exposed IL10 mouse model. Our findings demonstrate that oral administration of M13-NL prevents tumor development in AOM-exposed IL10 mice, suggesting that M13-NL is a promising oral drug formulation for preventing CAC.

References

Chassaing B, Srinivasan G, Delgado M, Young A, Gewirtz A, Vijay-Kumar M . Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One. 2012; 7(9):e44328. PMC: 3434182. DOI: 10.1371/journal.pone.0044328. View

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

Chang Z, Liu H, Leu Y, Hsu C, Lee T . Modulation of Gut Microbiota Combined with Upregulation of Intestinal Tight Junction Explains Anti-Inflammatory Effect of Corylin on Colitis-Associated Cancer in Mice. Int J Mol Sci. 2022; 23(5). PMC: 8910903. DOI: 10.3390/ijms23052667. View

Zhen Y, Luo C, Zhang H . Early detection of ulcerative colitis-associated colorectal cancer. Gastroenterol Rep (Oxf). 2018; 6(2):83-92. PMC: 5952942. DOI: 10.1093/gastro/goy010. View

Drozdzal S, Lechowicz K, Szostak B, Rosik J, Kotfis K, Machoy-Mokrzynska A . Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature. Pharmacol Res Perspect. 2021; 9(4):e00817. PMC: 8313037. DOI: 10.1002/prp2.817. View

Dai L, Li S, Hao Q, Zhou R, Zhou H, Lei W . Low-density lipoprotein: a versatile nanoscale platform for targeted delivery. Nanoscale Adv. 2023; 5(4):1011-1022. PMC: 9926902. DOI: 10.1039/d2na00883a. View

Long D, Alghoul Z, Sung J, Yang C, Merlin D . Oral administration of M13-loaded nanoliposomes is safe and effective to treat colitis-associated cancer in mice. Expert Opin Drug Deliv. 2023; 20(10):1443-1462. PMC: 10810011. DOI: 10.1080/17425247.2023.2231345. View

Newman P, Muscat J . Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review. Cancers (Basel). 2023; 15(4). PMC: 9954537. DOI: 10.3390/cancers15041102. View

Yang C, Zhang M, Merlin D . Advances in Plant-derived Edible Nanoparticle-based lipid Nano-drug Delivery Systems as Therapeutic Nanomedicines. J Mater Chem B. 2018; 6(9):1312-1321. PMC: 6053076. DOI: 10.1039/C7TB03207B. View

10.

Zhao L, Li J, Yu T, Chen G, Yuan Y, Chen Q . 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One. 2014; 9(4):e94208. PMC: 3978022. DOI: 10.1371/journal.pone.0094208. View

11.

Mundekkad D, Cho W . Nanoparticles in Clinical Translation for Cancer Therapy. Int J Mol Sci. 2022; 23(3). PMC: 8835852. DOI: 10.3390/ijms23031685. View

12.

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A . Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018; 10(2). PMC: 6027495. DOI: 10.3390/pharmaceutics10020057. View

13.

Gomes-Santos A, Moreira T, Castro-Junior A, Horta B, Lemos L, Cruz D . New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol. 2012; 2012:560817. PMC: 3287045. DOI: 10.1155/2012/560817. View

14.

Del Sordo R, Lougaris V, Bassotti G, Armuzzi A, Villanacci V . Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects. Clin Immunol. 2021; 234:108916. DOI: 10.1016/j.clim.2021.108916. View

15.

Rothemich A, Arthur J . The Azoxymethane/Il10 Model of Colitis-Associated Cancer (CAC). Methods Mol Biol. 2019; 1960:215-225. DOI: 10.1007/978-1-4939-9167-9_19. View

16.

De Robertis M, Massi E, Poeta M, Carotti S, Morini S, Cecchetelli L . The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011; 10:9. PMC: 3072657. DOI: 10.4103/1477-3163.78279. View

17.

Fang C, Chen J, Hsu B, Hussain B, Rathod J, Lee K . Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers. Microorganisms. 2021; 9(8). PMC: 8401100. DOI: 10.3390/microorganisms9081548. View

18.

Yang C, Zhang M, Lama S, Wang L, Merlin D . Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis. J Control Release. 2020; 323:293-310. PMC: 7299768. DOI: 10.1016/j.jconrel.2020.04.032. View

19.

Jin J, Zhu L, Chen M, Xu H, Wang H, Feng X . The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015; 9:923-42. PMC: 4494621. DOI: 10.2147/PPA.S87271. View

20.

Marynczak K, Wlodarczyk J, Sabatowska Z, Dziki A, Dziki L, Wlodarczyk M . Colitis-Associated Colorectal Cancer in Patients with Inflammatory Bowel Diseases in a Tertiary Referral Center: A Propensity Score Matching Analysis. J Clin Med. 2022; 11(3). PMC: 8836563. DOI: 10.3390/jcm11030866. View